Milestone Pharmaceuticals... (MIST)
NASDAQ: MIST
· Real-Time Price · USD
1.97
0.03 (1.55%)
At close: Sep 25, 2025, 3:59 PM
1.97
0.00%
After-hours: Sep 25, 2025, 04:58 PM EDT
1.55% (1D)
| Bid | 1.94 |
| Market Cap | 167.44M |
| Revenue (ttm) | 108K |
| Net Income (ttm) | -55.53M |
| EPS (ttm) | -0.84 |
| PE Ratio (ttm) | -2.35 |
| Forward PE | -2.35 |
| Analyst | Buy |
| Dividends | n/a |
| Ask | 2 |
| Volume | 880,962 |
| Avg. Volume (20D) | 1,555,960 |
| Open | 1.93 |
| Previous Close | 1.94 |
| Day's Range | 1.91 - 1.98 |
| 52-Week Range | 0.63 - 2.75 |
| Beta | 0.60 |
| Ex-Dividend Date | n/a |
About MIST
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol MIST
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for MIST stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsMilestone Pharmaceuticals Inc. is scheduled to release its earnings on
Nov 11, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
2 months ago
-39.06%
Milestone Pharmaceuticals shares are trading lower...
Unlock content with
Pro Subscription
2 months ago
-39.06%
Milestone Pharmaceuticals shares are trading lower after the company announced a public offering.
2 months ago · seekingalpha.com
Milestone Pharmaceuticals Remains A Buying Opportunity Despite Recent DilutionDespite the CRL setback and heavy dilution, we remain optimistic on etripamil's long-term market potential and Milestone's investment thesis. The recent $52.5 million equity raise was poorly timed and...
2 months ago · seekingalpha.com
Watch Milestone Pharmaceuticals For (Likely) Upcoming FDA Approval For CardamystI rate Milestone Pharmaceuticals Inc. a Strong Buy under $2, expecting FDA approval for Cardamyst in early 2026 after addressing recent regulatory setbacks. Cardamyst offers a unique, self-administere...